LON:SAR Sareum (SAR) Share Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free SAR Stock Alerts GBX 33.50 +10.25 (+44.09%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range 23.75▼ 3450-Day Range 10.25▼ 4052-Week Range 10▼ 149Volume5.87 million shsAverage Volume996,478 shsMarket Capitalization£24.04 millionP/E RatioN/ADividend Yield1.10%Price TargetGBX 304 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Sareum alerts: Email Address Sareum MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside807.5% UpsideGBX 304 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.01 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSareum has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSareum has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SAR. Previous Next 0.8 Dividend Strength Dividend YieldSareum pays a meaningful dividend of 1.10%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSareum does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SAR. Previous Next 2.0 News and Social Media Coverage News SentimentSareum has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.Search InterestOnly 8 people have searched for SAR on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sareum insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.07% of the stock of Sareum is held by insiders. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sareum is -670.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sareum is -670.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSareum has a P/B Ratio of 16.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Sareum Stock (LON:SAR)Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancerandcancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.Read More SAR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAR Stock News HeadlinesApril 16, 2024 | americanbankingnews.comSareum (LON:SAR) Shares Pass Below Fifty Day Moving Average of $26.03April 11, 2024 | lse.co.ukIssue of RiverFort Subscription SharesApril 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 4, 2024 | morningstar.comSareum Holdings PLC SARApril 4, 2024 | uk.investing.comSareum Holdings: A decisive period ahead for SDC-1801April 1, 2024 | msn.comTop 10 War Movies Based on Real Life You Can Watch on NetflixMarch 17, 2024 | lse.co.ukSareum Holdings touts new patent allowance for autoimmune therapyMarch 12, 2024 | lse.co.ukSareum shares slump on widened loss and funding talksApril 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...February 28, 2024 | finance.yahoo.comSareum Holdings plc (LON:SAR): Are Analysts Optimistic?February 19, 2024 | au.finance.yahoo.comSareum Holdings PLC (RYH0.SG)February 15, 2024 | lse.co.ukSareum hails safety profile for SDC-1801 after phase 1 trialJanuary 2, 2024 | lse.co.ukLONDON MARKET MIDDAY: London stocks make largely soft start to 2024January 2, 2024 | proactiveinvestors.com.auSareum surges as partner agrees licence for promising moleculeJanuary 2, 2024 | lse.co.ukSareum soars as partner agrees SRA737 licence with US biopharma firmDecember 14, 2023 | lse.co.ukEARNINGS AND TRADING: CleanTech raises GBP520,000 in open offerNovember 23, 2023 | fool.co.ukSareum shares just jumped 22%! Here’s whyNovember 9, 2023 | lse.co.ukEARNINGS AND TRADING: MetalNRG hails Gold Ridge findingsNovember 5, 2023 | msn.comThe 25 Best Sad Movies On Netflix That Will Give You All The FeelsNovember 3, 2023 | lse.co.ukSareum says patent notice in Japan boosts confidence in SDC-1801November 3, 2023 | marketwatch.comSareum Holdings Nears Patent for Autoimmune Disease Treatment in JapanOctober 13, 2023 | msn.comFTSE 100 Live: Jeremy Hunt warns on UK economy, Arm dips below IPO price, Next seals FatFace dealOctober 9, 2023 | lse.co.ukLONDON MARKET EARLY CALL: Higher call as high rate narrative settlesOctober 9, 2023 | lse.co.ukSareum says earnings down but product development going wellOctober 6, 2023 | lse.co.ukLONDON MARKET CLOSE: Stocks end higher, shaking off US nonfarms beatSeptember 5, 2023 | msn.comSareum doses first subjects in second stage of Phase 1a trial of SDC-1801September 4, 2023 | lse.co.ukSareum begins dosing participants in phase 1a trial for SDC-1801See More Headlines Receive SAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SAR CUSIPN/A CIKN/A Webwww.sareum.co.uk Phone+44-1223-497700FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 304 High Stock Price TargetGBX 304 Low Stock Price TargetGBX 304 Potential Upside/Downside+865.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-3,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.41% Return on Assets-74.35% Debt Debt-to-Equity RatioN/A Current Ratio2.28 Quick Ratio10.37 Sales & Book Value Annual Sales£47,204.00 Price / Sales478.87 Cash FlowGBX 2.78 per share Price / Cash Flow11.32 Book ValueGBX 2 per share Price / Book15.75Miscellaneous Outstanding Shares71,760,000Free FloatN/AMarket Cap£22.60 million OptionableNot Optionable Beta-0.69 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Timothy John Mitchell Ph.D. (Age 64)Founder, CEO & Executive Director Comp: $207.85kDr. John Charles Reader Ph.D. (Age 57)Founder, Chief Scientific Officer & Executive Director Comp: $205.8kMr. Clive H. W. Birch F.C.A. (Age 70)Senior Independent Non-Executive Director & Secretary Comp: $25kAlexandra HarrisonHead of IRKey CompetitorsSynairgenLON:SNGRealm TherapeuticsLON:RLMImmuPharmaLON:IMMBiVictriX TherapeuticsLON:BVXNetScientificLON:NSCIView All CompetitorsInsidersJohn C ReaderSold 50,426 sharesTotal: £2.87 M ($57.00/share)Clive BirchBought 2,479 shares on 9/4/2023Total: £203,278.00 ($82.00/share)View All Insider Transactions SAR Stock Analysis - Frequently Asked Questions Should I buy or sell Sareum stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sareum in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SAR shares. View SAR analyst ratings or view top-rated stocks. What is Sareum's stock price target for 2024? 1 analysts have issued 1 year price objectives for Sareum's shares. Their SAR share price targets range from GBX 304 to GBX 304. On average, they predict the company's stock price to reach GBX 304 in the next year. This suggests a possible upside of 807.5% from the stock's current price. View analysts price targets for SAR or view top-rated stocks among Wall Street analysts. How have SAR shares performed in 2024? Sareum's stock was trading at GBX 59.50 at the start of the year. Since then, SAR stock has decreased by 43.7% and is now trading at GBX 33.50. View the best growth stocks for 2024 here. What other stocks do shareholders of Sareum own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP), Madagascar Oil (MOIL), Summit Therapeutics (SMMT), Rockhopper Exploration (RKH) and How do I buy shares of Sareum? Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:SAR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sareum Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
